2-amino-4-phosphonobutyric acid has been researched along with Parkinson Disease, Secondary in 1 studies
2-amino-4-phosphonobutyric acid: glutamate antagonist in locust muscle; structure; do not confuse with L-AP4, which is the propionic acid version
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cuomo, D | 1 |
| Martella, G | 1 |
| Barabino, E | 1 |
| Platania, P | 1 |
| Vita, D | 1 |
| Madeo, G | 1 |
| Selvam, C | 1 |
| Goudet, C | 1 |
| Oueslati, N | 1 |
| Pin, JP | 1 |
| Acher, F | 1 |
| Pisani, A | 1 |
| Beurrier, C | 1 |
| Melon, C | 1 |
| Kerkerian-Le Goff, L | 1 |
| Gubellini, P | 1 |
1 other study available for 2-amino-4-phosphonobutyric acid and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment.
Topics: Aminobutyrates; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Electrophysiology; | 2009 |